Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study - PubMed (original) (raw)
Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study
Zoë Hyde et al. J Clin Endocrinol Metab. 2012 Jan.
Abstract
Context: Low testosterone is associated with all-cause mortality, but the relationship with cause-specific mortality is uncertain.
Objective: Our objective was to explore associations between testosterone and its related hormones and cause-specific mortality.
Design: This was a population-based cohort study.
Setting and participants: Demographic and clinical predictors of mortality, and testosterone, SHBG, and LH were measured from 2001-2004 in 3637 community-dwelling men aged 70-88 yr (mean, 77 yr).
Main outcome measure: Cause of death was obtained via electronic record linkage until December 31, 2008.
Results: During a mean follow-up period of 5.1 yr, there were 605 deaths. Of these, 207 [34.2%; 95% confidence interval (CI) = 30.4-38.1%] were due to cardiovascular disease (CVD), 231 to cancer (38.2%; 95% CI = 34.3-42.1%), 130 to respiratory diseases (21.5%; 95% CI = 18.2-24.8%), and 76 to other causes (12.6%; 95% CI = 9.9-15.2%). There were 39 deaths attributable to both cancer and respiratory diseases. Lower free testosterone (hazard ratio = 1.62; 95% CI = 1.20-2.19, for 100 vs. 280 pmol/liter), and higher SHBG and LH levels were associated with all-cause mortality. In cause-specific analyses, lower free testosterone (sub-hazard ratio = 1.71; 95% CI = 1.12-2.62, for 100 vs. 280 pmol/liter) and higher LH predicted CVD mortality, while higher SHBG predicted non-CVD mortality. Higher total testosterone and free testosterone levels (sub-hazard ratio = 1.96; 95% CI = 1.14-3.36, for 400 vs. 280 pmol/liter) were associated with mortality from lung cancer.
Conclusions: Low testosterone predicts mortality from CVD but is not associated with death from other causes. Prevention of androgen deficiency might improve cardiovascular outcomes but is unlikely to affect longevity otherwise.
Similar articles
- The Association of Reproductive Hormone Levels and All-Cause, Cancer, and Cardiovascular Disease Mortality in Men.
Holmboe SA, Vradi E, Jensen TK, Linneberg A, Husemoen LL, Scheike T, Skakkebæk NE, Juul A, Andersson AM. Holmboe SA, et al. J Clin Endocrinol Metab. 2015 Dec;100(12):4472-80. doi: 10.1210/jc.2015-2460. Epub 2015 Oct 21. J Clin Endocrinol Metab. 2015. PMID: 26488309 - Low serum levels of dehydroepiandrosterone sulfate predict all-cause and cardiovascular mortality in elderly Swedish men.
Ohlsson C, Labrie F, Barrett-Connor E, Karlsson MK, Ljunggren O, Vandenput L, Mellström D, Tivesten A. Ohlsson C, et al. J Clin Endocrinol Metab. 2010 Sep;95(9):4406-14. doi: 10.1210/jc.2010-0760. Epub 2010 Jul 7. J Clin Endocrinol Metab. 2010. PMID: 20610590 - Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromsø Study.
Vikan T, Schirmer H, Njølstad I, Svartberg J. Vikan T, et al. Eur J Endocrinol. 2009 Sep;161(3):435-42. doi: 10.1530/EJE-09-0284. Epub 2009 Jun 19. Eur J Endocrinol. 2009. PMID: 19542243 - Associations of Testosterone and Related Hormones With All-Cause and Cardiovascular Mortality and Incident Cardiovascular Disease in Men : Individual Participant Data Meta-analyses.
Yeap BB, Marriott RJ, Dwivedi G, Adams RJ, Antonio L, Ballantyne CM, Bauer DC, Bhasin S, Biggs ML, Cawthon PM, Couper DJ, Dobs AS, Flicker L, Handelsman DJ, Hankey GJ, Hannemann A, Haring R, Hsu B, Martin SA, Matsumoto AM, Mellström D, Ohlsson C, O'Neill TW, Orwoll ES, Quartagno M, Shores MM, Steveling A, Tivesten Å, Travison TG, Vanderschueren D, Wittert GA, Wu FCW, Murray K. Yeap BB, et al. Ann Intern Med. 2024 Jun;177(6):768-781. doi: 10.7326/M23-2781. Epub 2024 May 14. Ann Intern Med. 2024. PMID: 38739921 Review. - Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study.
Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, Forti G, Mannucci E, Maggi M. Corona G, et al. Eur J Endocrinol. 2011 Nov;165(5):687-701. doi: 10.1530/EJE-11-0447. Epub 2011 Aug 18. Eur J Endocrinol. 2011. PMID: 21852391 Review.
Cited by
- Aging impairs VEGF-mediated, androgen-dependent regulation of angiogenesis.
Lecce L, Lam YT, Lindsay LA, Yuen SC, Simpson PJ, Handelsman DJ, Ng MK. Lecce L, et al. Mol Endocrinol. 2014 Sep;28(9):1487-501. doi: 10.1210/me.2013-1405. Epub 2014 Jul 24. Mol Endocrinol. 2014. PMID: 25058601 Free PMC article. - The Association between Androgenic Hormone Levels and the Risk of Developing Coronary Artery Disease (CAD).
Allameh F, Pourmand G, Bozorgi A, Nekuie S, Namdari F. Allameh F, et al. Iran J Public Health. 2016 Jan;45(1):14-9. Iran J Public Health. 2016. PMID: 27057516 Free PMC article. - Testosterone replacement and cardiovascular safety: no straight and narrow!
Hans SS, Dhindsa SS, Chemitiganti R. Hans SS, et al. Clin Med Insights Cardiol. 2015 Apr 27;9:33-7. doi: 10.4137/CMC.S23395. eCollection 2015. Clin Med Insights Cardiol. 2015. PMID: 25983562 Free PMC article. Review. - Borderline-low testosterone levels are associated with lower left ventricular wall thickness in firefighters: An exploratory analysis.
Lofrano-Porto A, Soares EMKVK, Matias A, Porto LGG, Smith DL. Lofrano-Porto A, et al. Andrology. 2020 Nov;8(6):1753-1761. doi: 10.1111/andr.12860. Epub 2020 Sep 3. Andrology. 2020. PMID: 32633472 Free PMC article. - The role of testosterone therapy in cardiovascular mortality: culprit or innocent bystander?
Tanna MS, Schwartzbard A, Berger JS, Alukal J, Weintraub H. Tanna MS, et al. Curr Atheroscler Rep. 2015 Mar;17(3):490. doi: 10.1007/s11883-015-0490-0. Curr Atheroscler Rep. 2015. PMID: 25687258 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous